Altered response to ibutilide in a heart failure model

Sumeet S. Chugh, Susan B. Johnson, Douglas L Packer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: Despite the frequent use of anti-arrhythmic drugs in the general population, the electrophysiologic effects of these agents have not been elucidated in congestive heart failure (CHF). Methods: To examine the impact of left ventricular dysfunction on actions of type III anti-arrhythmic drugs, we evaluated the actions of ibutilide in a canine model of pacing-induced dilated cardiomyopathy. Following ablation of the atrioventricular node, effects on action potential duration at 90% (APD 90) were compared in vivo, between eight CHF animals and seven controls. Monophasic action potential recordings were obtained from right and left ventricular endocardium/epicardium during and after three doses of ibutilide (0.01, 0.02 and 0.05 mg/kg), at pacing cycle lengths of 300-1000 ms. Results: APD 90 prolongation with ibutilide (0.01 mg/kg) was significantly greater in CHF vs. controls (P=0.0026, ANOVA). However, plasma ibutilide levels at this dose, were not significantly different between the two groups. In CHF, maximal effects were observed at the lowest dose, whereas effects were gradual and dose-dependent in controls. With ibutilide administration (0.01 mg/kg), an increased dispersion of left-right ventricular APD 90 was observed in CHF, but not in controls (P=0.03). A trend was observed, for increased incidence of non-sustained polymorphic ventricular tachycardia in CHF. Conclusions: In the presence of CHF, the actions of ibutilide are altered significantly. These findings may reflect altered tissue effects, as a consequence of myocardial electrical remodeling in CHF. (C) 2001 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalCardiovascular Research
Volume49
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Heart Failure
Action Potentials
Anti-Arrhythmia Agents
Atrial Remodeling
Endocardium
Atrioventricular Node
ibutilide
Pericardium
Dilated Cardiomyopathy
Left Ventricular Dysfunction
Ventricular Tachycardia
Pharmaceutical Preparations
Canidae
Analysis of Variance
Incidence
Population

Keywords

  • Antiarrhythmic agents
  • Heart failure
  • K-channel
  • Remodeling
  • Ventricular arrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Altered response to ibutilide in a heart failure model. / Chugh, Sumeet S.; Johnson, Susan B.; Packer, Douglas L.

In: Cardiovascular Research, Vol. 49, No. 1, 2001, p. 94-102.

Research output: Contribution to journalArticle

Chugh, Sumeet S. ; Johnson, Susan B. ; Packer, Douglas L. / Altered response to ibutilide in a heart failure model. In: Cardiovascular Research. 2001 ; Vol. 49, No. 1. pp. 94-102.
@article{3ba2e2ad63ec4d91a903da3d98cef0d0,
title = "Altered response to ibutilide in a heart failure model",
abstract = "Objective: Despite the frequent use of anti-arrhythmic drugs in the general population, the electrophysiologic effects of these agents have not been elucidated in congestive heart failure (CHF). Methods: To examine the impact of left ventricular dysfunction on actions of type III anti-arrhythmic drugs, we evaluated the actions of ibutilide in a canine model of pacing-induced dilated cardiomyopathy. Following ablation of the atrioventricular node, effects on action potential duration at 90{\%} (APD 90) were compared in vivo, between eight CHF animals and seven controls. Monophasic action potential recordings were obtained from right and left ventricular endocardium/epicardium during and after three doses of ibutilide (0.01, 0.02 and 0.05 mg/kg), at pacing cycle lengths of 300-1000 ms. Results: APD 90 prolongation with ibutilide (0.01 mg/kg) was significantly greater in CHF vs. controls (P=0.0026, ANOVA). However, plasma ibutilide levels at this dose, were not significantly different between the two groups. In CHF, maximal effects were observed at the lowest dose, whereas effects were gradual and dose-dependent in controls. With ibutilide administration (0.01 mg/kg), an increased dispersion of left-right ventricular APD 90 was observed in CHF, but not in controls (P=0.03). A trend was observed, for increased incidence of non-sustained polymorphic ventricular tachycardia in CHF. Conclusions: In the presence of CHF, the actions of ibutilide are altered significantly. These findings may reflect altered tissue effects, as a consequence of myocardial electrical remodeling in CHF. (C) 2001 Elsevier Science B.V.",
keywords = "Antiarrhythmic agents, Heart failure, K-channel, Remodeling, Ventricular arrhythmias",
author = "Chugh, {Sumeet S.} and Johnson, {Susan B.} and Packer, {Douglas L}",
year = "2001",
doi = "10.1016/S0008-6363(00)00235-2",
language = "English (US)",
volume = "49",
pages = "94--102",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Altered response to ibutilide in a heart failure model

AU - Chugh, Sumeet S.

AU - Johnson, Susan B.

AU - Packer, Douglas L

PY - 2001

Y1 - 2001

N2 - Objective: Despite the frequent use of anti-arrhythmic drugs in the general population, the electrophysiologic effects of these agents have not been elucidated in congestive heart failure (CHF). Methods: To examine the impact of left ventricular dysfunction on actions of type III anti-arrhythmic drugs, we evaluated the actions of ibutilide in a canine model of pacing-induced dilated cardiomyopathy. Following ablation of the atrioventricular node, effects on action potential duration at 90% (APD 90) were compared in vivo, between eight CHF animals and seven controls. Monophasic action potential recordings were obtained from right and left ventricular endocardium/epicardium during and after three doses of ibutilide (0.01, 0.02 and 0.05 mg/kg), at pacing cycle lengths of 300-1000 ms. Results: APD 90 prolongation with ibutilide (0.01 mg/kg) was significantly greater in CHF vs. controls (P=0.0026, ANOVA). However, plasma ibutilide levels at this dose, were not significantly different between the two groups. In CHF, maximal effects were observed at the lowest dose, whereas effects were gradual and dose-dependent in controls. With ibutilide administration (0.01 mg/kg), an increased dispersion of left-right ventricular APD 90 was observed in CHF, but not in controls (P=0.03). A trend was observed, for increased incidence of non-sustained polymorphic ventricular tachycardia in CHF. Conclusions: In the presence of CHF, the actions of ibutilide are altered significantly. These findings may reflect altered tissue effects, as a consequence of myocardial electrical remodeling in CHF. (C) 2001 Elsevier Science B.V.

AB - Objective: Despite the frequent use of anti-arrhythmic drugs in the general population, the electrophysiologic effects of these agents have not been elucidated in congestive heart failure (CHF). Methods: To examine the impact of left ventricular dysfunction on actions of type III anti-arrhythmic drugs, we evaluated the actions of ibutilide in a canine model of pacing-induced dilated cardiomyopathy. Following ablation of the atrioventricular node, effects on action potential duration at 90% (APD 90) were compared in vivo, between eight CHF animals and seven controls. Monophasic action potential recordings were obtained from right and left ventricular endocardium/epicardium during and after three doses of ibutilide (0.01, 0.02 and 0.05 mg/kg), at pacing cycle lengths of 300-1000 ms. Results: APD 90 prolongation with ibutilide (0.01 mg/kg) was significantly greater in CHF vs. controls (P=0.0026, ANOVA). However, plasma ibutilide levels at this dose, were not significantly different between the two groups. In CHF, maximal effects were observed at the lowest dose, whereas effects were gradual and dose-dependent in controls. With ibutilide administration (0.01 mg/kg), an increased dispersion of left-right ventricular APD 90 was observed in CHF, but not in controls (P=0.03). A trend was observed, for increased incidence of non-sustained polymorphic ventricular tachycardia in CHF. Conclusions: In the presence of CHF, the actions of ibutilide are altered significantly. These findings may reflect altered tissue effects, as a consequence of myocardial electrical remodeling in CHF. (C) 2001 Elsevier Science B.V.

KW - Antiarrhythmic agents

KW - Heart failure

KW - K-channel

KW - Remodeling

KW - Ventricular arrhythmias

UR - http://www.scopus.com/inward/record.url?scp=0034747793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034747793&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(00)00235-2

DO - 10.1016/S0008-6363(00)00235-2

M3 - Article

C2 - 11121800

AN - SCOPUS:0034747793

VL - 49

SP - 94

EP - 102

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -